A Study of SHR-1918 In Participants With Hypertriglyceridemia

Exclusion Criteria10

• History of severe allergies/hypersensitivity reactions, or clinically significant allergies/hypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures.
• Received or are currently receiving treatment with monoclonal antibodies, siRNA-based drugs, or ASO-based drugs targeting the same target prior to screening.
• Have a history of pancreatitis prior to screening or randomization.
• Acute ischemic ASCVD events within 3 months prior to screening or randomization.
• Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization.
• Malignant tumors within 5 years.
• Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening.
• Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization.
• Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension.
• Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period.